Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetes
- Autores
- Joison, Agustín Néstor; Baiardi, Gustavo Carlos
- Año de publicación
- 2016
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- The acute coronary syndrome is a consequence of coronary artery disease. Creatine Kinase MB is a cardiac biochemical marker used in the diagnosis and risk stratification of patients. The diabetes is a pathology associated to acute coronary syndrome non–ST segment elevation that change the cardiac conditions, in this sense, our objective was to evaluate the modifications of cardiac biomarkers values in diabetic patients. Materials and methods: A retrospective study included 155 patients of both sexes, ages ranging from 31 to 92 years old, admitted to the coronary unit of the “Reina Fabiola†Clinic, Córdoba, Argentina was performed in the period 2014-2015. Body mass index, time consultation pain, plasmatic Creatine Kinase isoenzyme MB activity and Troponin I levels were measured. The patients were stratified into two groups: without cardiovascular risk pathologies (Control group), n = 7; and with only type II diabetes, n = 64 treated with therapeutic doses of metformin (n= 37), and glibenclamide plus glizipide (n= 27). Results: cTnI levels were lower in both pharmacological treatments at 12 hrs when the values in control reach the highest. Similarly, CK-MB activity was lower at 8 hrs in both treatments; however at 12 hrs these values were lower only with metformin but not in glibenclamide plus glizipide treatment. These results could be showing an interaction between diabetes and pharmacological treatment upon the biomarkers values. Conclusion: The use of hypoglycemic drugs and the glycometabolic state are conditions that could modify CK-MB and cTnI release/clearance balance at 8 and 12 hrs after admission to the coronary unit.
Fil: Joison, Agustín Néstor. Universidad Catolica de Córdoba. Facultad de Ciencias Químicas; Argentina
Fil: Baiardi, Gustavo Carlos. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones Biológicas y Tecnológicas. Universidad Nacional de Córdoba. Facultad de Ciencias Exactas, Físicas y Naturales. Instituto de Investigaciones Biológicas y Tecnológicas; Argentina - Materia
-
CORONARY SYNDROME
CREATINE KINASE MB
DIABETES
TRPONIN I - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
.jpg)
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/42664
Ver los metadatos del registro completo
| id |
CONICETDig_1a982b04058298e41412abb4c095a34f |
|---|---|
| oai_identifier_str |
oai:ri.conicet.gov.ar:11336/42664 |
| network_acronym_str |
CONICETDig |
| repository_id_str |
3498 |
| network_name_str |
CONICET Digital (CONICET) |
| spelling |
Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetesJoison, Agustín NéstorBaiardi, Gustavo CarlosCORONARY SYNDROMECREATINE KINASE MBDIABETESTRPONIN Ihttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3The acute coronary syndrome is a consequence of coronary artery disease. Creatine Kinase MB is a cardiac biochemical marker used in the diagnosis and risk stratification of patients. The diabetes is a pathology associated to acute coronary syndrome non–ST segment elevation that change the cardiac conditions, in this sense, our objective was to evaluate the modifications of cardiac biomarkers values in diabetic patients. Materials and methods: A retrospective study included 155 patients of both sexes, ages ranging from 31 to 92 years old, admitted to the coronary unit of the “Reina Fabiola†Clinic, Córdoba, Argentina was performed in the period 2014-2015. Body mass index, time consultation pain, plasmatic Creatine Kinase isoenzyme MB activity and Troponin I levels were measured. The patients were stratified into two groups: without cardiovascular risk pathologies (Control group), n = 7; and with only type II diabetes, n = 64 treated with therapeutic doses of metformin (n= 37), and glibenclamide plus glizipide (n= 27). Results: cTnI levels were lower in both pharmacological treatments at 12 hrs when the values in control reach the highest. Similarly, CK-MB activity was lower at 8 hrs in both treatments; however at 12 hrs these values were lower only with metformin but not in glibenclamide plus glizipide treatment. These results could be showing an interaction between diabetes and pharmacological treatment upon the biomarkers values. Conclusion: The use of hypoglycemic drugs and the glycometabolic state are conditions that could modify CK-MB and cTnI release/clearance balance at 8 and 12 hrs after admission to the coronary unit.Fil: Joison, Agustín Néstor. Universidad Catolica de Córdoba. Facultad de Ciencias Químicas; ArgentinaFil: Baiardi, Gustavo Carlos. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones Biológicas y Tecnológicas. Universidad Nacional de Córdoba. Facultad de Ciencias Exactas, Físicas y Naturales. Instituto de Investigaciones Biológicas y Tecnológicas; ArgentinaIJMHS2016-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/42664Joison, Agustín Néstor; Baiardi, Gustavo Carlos; Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetes; IJMHS; International Journal of Medical and Health Sciences; 5; 1; 1-2016; 32-372277-4505CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://www.ijmhs.net/journals-aid-312.htmlinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:25:51Zoai:ri.conicet.gov.ar:11336/42664instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:25:51.887CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
| dc.title.none.fl_str_mv |
Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetes |
| title |
Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetes |
| spellingShingle |
Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetes Joison, Agustín Néstor CORONARY SYNDROME CREATINE KINASE MB DIABETES TRPONIN I |
| title_short |
Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetes |
| title_full |
Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetes |
| title_fullStr |
Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetes |
| title_full_unstemmed |
Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetes |
| title_sort |
Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetes |
| dc.creator.none.fl_str_mv |
Joison, Agustín Néstor Baiardi, Gustavo Carlos |
| author |
Joison, Agustín Néstor |
| author_facet |
Joison, Agustín Néstor Baiardi, Gustavo Carlos |
| author_role |
author |
| author2 |
Baiardi, Gustavo Carlos |
| author2_role |
author |
| dc.subject.none.fl_str_mv |
CORONARY SYNDROME CREATINE KINASE MB DIABETES TRPONIN I |
| topic |
CORONARY SYNDROME CREATINE KINASE MB DIABETES TRPONIN I |
| purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.2 https://purl.org/becyt/ford/3 |
| dc.description.none.fl_txt_mv |
The acute coronary syndrome is a consequence of coronary artery disease. Creatine Kinase MB is a cardiac biochemical marker used in the diagnosis and risk stratification of patients. The diabetes is a pathology associated to acute coronary syndrome non–ST segment elevation that change the cardiac conditions, in this sense, our objective was to evaluate the modifications of cardiac biomarkers values in diabetic patients. Materials and methods: A retrospective study included 155 patients of both sexes, ages ranging from 31 to 92 years old, admitted to the coronary unit of the “Reina Fabiola†Clinic, Córdoba, Argentina was performed in the period 2014-2015. Body mass index, time consultation pain, plasmatic Creatine Kinase isoenzyme MB activity and Troponin I levels were measured. The patients were stratified into two groups: without cardiovascular risk pathologies (Control group), n = 7; and with only type II diabetes, n = 64 treated with therapeutic doses of metformin (n= 37), and glibenclamide plus glizipide (n= 27). Results: cTnI levels were lower in both pharmacological treatments at 12 hrs when the values in control reach the highest. Similarly, CK-MB activity was lower at 8 hrs in both treatments; however at 12 hrs these values were lower only with metformin but not in glibenclamide plus glizipide treatment. These results could be showing an interaction between diabetes and pharmacological treatment upon the biomarkers values. Conclusion: The use of hypoglycemic drugs and the glycometabolic state are conditions that could modify CK-MB and cTnI release/clearance balance at 8 and 12 hrs after admission to the coronary unit. Fil: Joison, Agustín Néstor. Universidad Catolica de Córdoba. Facultad de Ciencias Químicas; Argentina Fil: Baiardi, Gustavo Carlos. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones Biológicas y Tecnológicas. Universidad Nacional de Córdoba. Facultad de Ciencias Exactas, Físicas y Naturales. Instituto de Investigaciones Biológicas y Tecnológicas; Argentina |
| description |
The acute coronary syndrome is a consequence of coronary artery disease. Creatine Kinase MB is a cardiac biochemical marker used in the diagnosis and risk stratification of patients. The diabetes is a pathology associated to acute coronary syndrome non–ST segment elevation that change the cardiac conditions, in this sense, our objective was to evaluate the modifications of cardiac biomarkers values in diabetic patients. Materials and methods: A retrospective study included 155 patients of both sexes, ages ranging from 31 to 92 years old, admitted to the coronary unit of the “Reina Fabiola†Clinic, Córdoba, Argentina was performed in the period 2014-2015. Body mass index, time consultation pain, plasmatic Creatine Kinase isoenzyme MB activity and Troponin I levels were measured. The patients were stratified into two groups: without cardiovascular risk pathologies (Control group), n = 7; and with only type II diabetes, n = 64 treated with therapeutic doses of metformin (n= 37), and glibenclamide plus glizipide (n= 27). Results: cTnI levels were lower in both pharmacological treatments at 12 hrs when the values in control reach the highest. Similarly, CK-MB activity was lower at 8 hrs in both treatments; however at 12 hrs these values were lower only with metformin but not in glibenclamide plus glizipide treatment. These results could be showing an interaction between diabetes and pharmacological treatment upon the biomarkers values. Conclusion: The use of hypoglycemic drugs and the glycometabolic state are conditions that could modify CK-MB and cTnI release/clearance balance at 8 and 12 hrs after admission to the coronary unit. |
| publishDate |
2016 |
| dc.date.none.fl_str_mv |
2016-01 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/42664 Joison, Agustín Néstor; Baiardi, Gustavo Carlos; Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetes; IJMHS; International Journal of Medical and Health Sciences; 5; 1; 1-2016; 32-37 2277-4505 CONICET Digital CONICET |
| url |
http://hdl.handle.net/11336/42664 |
| identifier_str_mv |
Joison, Agustín Néstor; Baiardi, Gustavo Carlos; Effect of pharmacological treatment on cardiac biomarkers in patients with acute coronary syndrome of non–ST segment elevation with Type-2 diabetes; IJMHS; International Journal of Medical and Health Sciences; 5; 1; 1-2016; 32-37 2277-4505 CONICET Digital CONICET |
| dc.language.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/http://www.ijmhs.net/journals-aid-312.html |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
| dc.format.none.fl_str_mv |
application/pdf application/pdf |
| dc.publisher.none.fl_str_mv |
IJMHS |
| publisher.none.fl_str_mv |
IJMHS |
| dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
| reponame_str |
CONICET Digital (CONICET) |
| collection |
CONICET Digital (CONICET) |
| instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
| _version_ |
1846781811558973440 |
| score |
12.982451 |